Faisal G. Sukhtian.

ISELIN, N.J.—Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve U.S. Food and Drug Administration (FDA) approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, has announced Faisal G. Sukhtian has been appointed as chairman of the board of directors, effective immediately. According to the company, Sukhtian will assume the role from Randy Thurman, who will remain on the board as lead independent director. “On behalf of the board of directors, management, and employees of Outlook Therapeutics, I want to extend my deepest gratitude to Randy for his extraordinary leadership and unwavering commitment," said Sukhtian.

He continued, "Under his guidance, Outlook Therapeutics has evolved from a preclinical biotech to a company preparing to launch our first product. Randy’s decades of experience in the biopharmaceutical industry, strategic insight and mentorship have been invaluable in shaping the company’s trajectory. I am personally grateful for his continued role as lead independent director, and I look forward to continuing to work closely with him as we embark on this exciting next phase.”
 
Sukhtian has served as a member of Outlook Therapeutics’ board of directors since 2017. Over the course of his career, he has amassed experience in operations, strategy development and mergers and acquisitions in the biopharma and life sciences space. He currently serves as executive director at GMS Holdings and oversees a number of investments within the GMS Holdings portfolio.

 
“I am honored to take on the role of chairman and deeply appreciate the trust placed in me by the board," said Sukhtian. "This is a pivotal year for Outlook Therapeutics as we prepare to launch Lytenava in the EU and the UK, bringing an important new treatment option to patients in those markets. At the same time, we remain focused on completing a timely FDA resubmission in the United States and advancing the development of our asset to expand its scope and reach to patients worldwide. I look forward to working with our exceptional management team and board to execute on our vision to deliver this important treatment to patients.”